Squarer Ron — SEC Form 4 filings
SEC reporting owner CIK 1454001. 13 Form 4 filings on record with FilingPulse; latest filed 2026-07-15.
Transaction summary — filings shown
Covers all 13 filings on record, filed 2024-01-18 to 2026-07-15. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 1 leg across 1 filing — 6,995 shares, $20,216 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 22.
- Largest priced transaction: sale of 6,995 shares @ $2.89 ($20,216) in ADC Therapeutics SA, filed 2024-06-18.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| ADC Therapeutics SA (ADCT) | Director | 5 | — | 1 leg · 6,995 sh · $20,216 | 5 |
| Deciphera Pharmaceuticals, Inc. | Director | 2 | — | — | 6 |
| Travere Therapeutics, Inc. (TVTX) | Director | 3 | — | — | 6 |
| Nuvalent, Inc. (NUVL) | Director | 3 | — | — | 5 |
Form 4 filings — Squarer Ron
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-07-15 | 4 | Nuvalent, Inc. (NUVL) | Disposition to issuer (D): 6,281 · Disposition to issuer (D): 4,418 (derivative) | EDGAR |
| 2026-06-18 | 4 | Nuvalent, Inc. (NUVL) | Grant/award (A): 3,444 @ $0 | EDGAR |
| 2026-06-03 | 4 | ADC Therapeutics SA (ADCT) | Grant/award (A): 45,000 @ $0 · Tax withholding (F): 15,196 @ $3.08 | EDGAR |
| 2026-05-21 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 4,000 @ $0 · Grant/award (A): 12,000 (derivative) @ $0 | EDGAR |
| 2025-12-11 | 4 | Nuvalent, Inc. (NUVL) | Grant/award (A): 2,837 @ $0 · Grant/award (A): 4,418 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | ADC Therapeutics SA (ADCT) | Tax withholding (F): 15,184 @ $3.58 | EDGAR |
| 2025-06-05 | 4 | ADC Therapeutics SA (ADCT) | Grant/award (A): 40,000 @ $0 | EDGAR |
| 2025-05-16 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 6,500 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | ADC Therapeutics SA (ADCT) | Sale (S): 6,995 @ $2.89 | EDGAR |
| 2024-06-14 | 4 | ADC Therapeutics SA (ADCT) | Grant/award (A): 40,000 @ $0 | EDGAR |
| 2024-06-11 | 4 | Deciphera Pharmaceuticals, Inc. | Disposition to issuer (D): 9,570 (derivative) · Disposition to issuer (D): 18,500 (derivative) · Disposition to issuer (D): 3,269 (derivative) · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 4,727 (derivative) | EDGAR |
| 2024-05-10 | 4 | Travere Therapeutics, Inc. (TVTX) | Grant/award (A): 6,500 @ $0 · Grant/award (A): 19,500 (derivative) @ $0 | EDGAR |
| 2024-01-18 | 4 | Deciphera Pharmaceuticals, Inc. (DCPH) | Grant/award (A): 4,727 (derivative) @ $10.58 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1454001 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →